West Pharmaceutical Services, Inc.

West Pharmaceutical's 39.7 P/E ratio stands nearly double the typical medical device peer average, yet the stock sits below its 52-week high with an RSI of 68.2—territory suggesting momentum without complete euphoria. The 4.4% short float remains modest, indicating limited squeeze potential. The premium valuation relative to surgical instrument peers suggests the market is pricing in sustained high-margin growth and market share gains, likely justified by WST's dominant position in injectable drug delivery systems. However, at this valuation and momentum level, the risk-reward favors those already positioned; fresh entries face limited margin of safety given that surgical device demand could prove cyclical if healthcare spending tightens.